180 related articles for article (PubMed ID: 36823378)
21. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
23. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
24. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.
Menon S; Dibble CC; Talbott G; Hoxhaj G; Valvezan AJ; Takahashi H; Cantley LC; Manning BD
Cell; 2014 Feb; 156(4):771-85. PubMed ID: 24529379
[TBL] [Abstract][Full Text] [Related]
25. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
Zhang HH; Huang J; Düvel K; Boback B; Wu S; Squillace RM; Wu CL; Manning BD
PLoS One; 2009 Jul; 4(7):e6189. PubMed ID: 19593385
[TBL] [Abstract][Full Text] [Related]
26. TSC2 mediates hyperosmotic stress-induced inactivation of mTORC1.
Plescher M; Teleman AA; Demetriades C
Sci Rep; 2015 Sep; 5():13828. PubMed ID: 26345496
[TBL] [Abstract][Full Text] [Related]
27. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H
Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic Avian Reovirus p17-Modulated Inhibition of mTORC1 by Enhancement of Endogenous mTORC1 Inhibitors Binding to mTORC1 To Disrupt Its Assembly and Accumulation on Lysosomes.
Li JY; Huang WR; Liao TL; Nielsen BL; Liu HJ
J Virol; 2022 Sep; 96(17):e0083622. PubMed ID: 35946936
[TBL] [Abstract][Full Text] [Related]
30. Bcat1 is controlled by Tsc2/mTORC1 pathway at expression levels and its deficiency together with Bcat2 inactivation suppresses the growth of a Tsc2
Nishikawa K; Mezawa Y; Kobayashi T
Genes Cells; 2023 Jun; 28(6):447-456. PubMed ID: 36965015
[TBL] [Abstract][Full Text] [Related]
31. Design of negative-regulating proteins of Rheb/mTORC1 with much-reduced sizes of the tuberous sclerosis protein complex.
Fu W; Wu G
Protein Sci; 2023 Aug; 32(8):e4731. PubMed ID: 37462942
[TBL] [Abstract][Full Text] [Related]
32. TSC2 regulates lysosome biogenesis via a non-canonical RAGC and TFEB-dependent mechanism.
Alesi N; Akl EW; Khabibullin D; Liu HJ; Nidhiry AS; Garner ER; Filippakis H; Lam HC; Shi W; Viswanathan SR; Morroni M; Ferguson SM; Henske EP
Nat Commun; 2021 Jul; 12(1):4245. PubMed ID: 34253722
[TBL] [Abstract][Full Text] [Related]
33. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
34. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
[TBL] [Abstract][Full Text] [Related]
35. Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide.
Parkhitko AA; Priolo C; Coloff JL; Yun J; Wu JJ; Mizumura K; Xu W; Malinowska IA; Yu J; Kwiatkowski DJ; Locasale JW; Asara JM; Choi AM; Finkel T; Henske EP
Mol Cancer Res; 2014 Jan; 12(1):48-57. PubMed ID: 24296756
[TBL] [Abstract][Full Text] [Related]
36. mTORC1 silencing during intestinal epithelial Caco-2 cell differentiation is mediated by the activation of the AMPK/TSC2 pathway.
Kaur H; Moreau R
Biochem Biophys Res Commun; 2021 Mar; 545():183-188. PubMed ID: 33561653
[TBL] [Abstract][Full Text] [Related]
37. Methionine controls insulin/mammalian target of rapamycin complex 1 activity by modulating tuberous sclerosis complex 2 stability.
Gen S; Matsumoto Y; Suzuki T; Inoue J; Yamamoto Y
Biochem Biophys Res Commun; 2021 Feb; 541():84-89. PubMed ID: 33482580
[TBL] [Abstract][Full Text] [Related]
38. Loss of TSC2 confers resistance to ceramide and nutrient deprivation.
Guenther GG; Liu G; Ramirez MU; McMonigle RJ; Kim SM; McCracken AN; Joo Y; Ushach I; Nguyen NL; Edinger AL
Oncogene; 2014 Apr; 33(14):1776-87. PubMed ID: 23604129
[TBL] [Abstract][Full Text] [Related]
39. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.
Kang YJ; Lu MK; Guan KL
Cell Death Differ; 2011 Jan; 18(1):133-44. PubMed ID: 20616807
[TBL] [Abstract][Full Text] [Related]
40. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.
Wolff NC; Vega-Rubin-de-Celis S; Xie XJ; Castrillon DH; Kabbani W; Brugarolas J
Mol Cell Biol; 2011 May; 31(9):1870-84. PubMed ID: 21383064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
